BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

FemHealth Focus

Project ACTIVE Two Point Zero Launches to Strengthen Cervical Cancer Care Across Southeast Asia

A major step forward in regional collaboration for cancer care was announced today with the launch of Project ACTIVE 2.0 (Advancing Cervical Cancer Tr...

November 14, 2025 | News

Akeso Secures Fourth Breakthrough Therapy Designation for Ivonescimab in Combination Therapy for Triple-Negative Breast Cancer

Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for fi...

November 04, 2025 | News

Novartis Review Reveals Fear of Recurrence as a Major Unmet Need in Breast Cancer Survivorship Across Asia Pacific and the Middle East

A new targeted literature review finds the fear of recurrence a major unmet need in breast cancer survivorship, often found to affect at least two in fiv...

October 31, 2025 | Report

Alphamab Oncology and CSPC’s HER2-Targeting ADC JSKN003 Receives Breakthrough Therapy Designation in China for Advanced Colorectal Cancer

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targ...

October 21, 2025 | News

Sichuan Kelun-Biotech’s Trastuzumab Botidotin Approved in China for HER2-Positive Metastatic Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor recep...

October 20, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU delivers second positive phase 3 win in HER2 positive early breast cancer

Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become...

September 30, 2025 | News

Desert Harvest Launches First Menopause Supplement with Human-Identical Lactoferrin

Desert Harvest, a clinically trusted leader in pelvic and hormonal wellness, announced the launch of the first menopause supplement to feature human-i...

September 29, 2025 | News

Noul Secures FDA Registration for miLab™ CER Cervical Cancer Diagnostic, Paving Way for US Market Entry

Noul Co., Ltd. (CEO: David Lim), a medical AI company specializing in blood and cancer diagnostics, announced that FDA registration has been completed...

September 26, 2025 | News

Hengrui Pharma Grants Glenmark Exclusive Global Licence for HER2-Targeted ADC Trastuzumab Rezetecan

Hengrui Pharma, a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced that it has entered ...

September 25, 2025 | News

Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer

Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...

September 16, 2025 | News

Biostar Pharma Doses First Patients in Two Global Phase II/III Trials of Oral Utidelone Capsule for Gastric and Ovarian Cancers

Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. ("Biostar", Stock Code: 2563.HK) which is a synthetic biolo...

September 16, 2025 | News

Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer

Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...

September 15, 2025 | News

Kazia’s Paxalisib Disrupts Circulating Tumour Cell Clusters in HER2-Positive Metastatic Breast Cancer Study

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program...

September 12, 2025 | News

Siemens Healthineers–YouGov Survey Reveals Fragmented Cancer Care Pathway in Southeast Asia, Underscoring Need for Integrated Solutions

YouGov survey finds strong belief in value of early detection (78%) but low screening uptake (26%) 80% of respondents aware post-treatment care exists...

September 10, 2025 | Report

Stay Connected